Type 2 Diabetes and Osteoporosis: A Guide to Optimal Management

Teriparatide in patients with osteoporosis and type 2 diabetes

(2016) Ann V. Schwartz et al.   BONE

Efficacy of Osteoporosis Therapies in Diabetic Patients

(2016) Ann V. Schwartz   CALCIFIED TISSUE INTERNATIONAL

Effect of teriparatide treatment on endothelial function, glucose metabolism and inflammation markers in patients with postmenopausal osteoporosis

(2016) Ozgen Celer et al.   CLINICAL ENDOCRINOLOGY

Skeletal Metabolism, Fracture Risk, and Fracture Outcomes in Type 1 and Type 2 Diabetes

(2016) Deborah E. Sellmeyer et al.   DIABETES

Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial

(2016) Robert G. Josse et al.   DIABETES OBESITY & METABOLISM

Antiresorptive therapy and newly diagnosed diabetes in women: a historical cohort study

(2016) S. Yang et al.   DIABETES OBESITY & METABOLISM

Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials

(2016) H. L. Tang et al.   DIABETES OBESITY & METABOLISM

COMPARISON OF THE LONG-TERM EFFECTS OF LIRAGLUTIDE AND GLIMEPIRIDE MONOTHERAPY ON BONE MINERAL DENSITY IN PATIENTS WITH TYPE 2 DIABETES

(2016) Matthew P. Gilbert et al.   Endocrine Practice

Bariatric Surgery

(2016) Sidra Azim et al.   ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA

Inpatient Diabetes Management in the Twenty-First Century

(2016) Natasha B. Khazai et al.   ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA

Association Between Insulin Resistance and Bone Structure in Nondiabetic Postmenopausal Women

(2016) Vikram V. Shanbhogue et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Longer Duration of Diabetes Strongly Impacts Fracture Risk Assessment: The Manitoba BMD Cohort

(2016) Sumit R. Majumdar et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin

(2016) John P. Bilezikian et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus

(2016) Nelson B. Watts et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Fracture risk after bariatric surgery

(2016) David Holmes   Nature Reviews Endocrinology

Visit-to-visit variation of fasting plasma glucose is a predictor of hip fracture in older persons with type 2 diabetes: the Taiwan Diabetes Study

(2016) J. I.-H. Chiang et al.   OSTEOPOROSIS INTERNATIONAL

Risk of fractures and diabetes medications: a nationwide cohort study

(2016) H. J. Choi et al.   OSTEOPOROSIS INTERNATIONAL

Denosumab Inhibition of RANKL and Insulin Resistance in Postmenopausal Women with Osteoporosis

(2015) Antonino Lasco et al.   CALCIFIED TISSUE INTERNATIONAL

Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial

(2015) Ofri Mosenzon et al.   DIABETES CARE

3. Foundations of Care and Comprehensive Medical Evaluation

(2015)   DIABETES CARE

Effects of TZD Use and Discontinuation on Fracture Rates in ACCORD Bone Study

(2015) Ann V. Schwartz et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Bisphosphonates and Glucose Homeostasis: A Population-Based, Retrospective Cohort Study

(2015) Konstantinos A. Toulis et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women

(2015) Eva W. Iepsen et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Fracture Risk After Bariatric Surgery

(2015) Chia-Wen Lu et al.   MEDICINE

Erratum to: Clinician’s guide to prevention and treatment of osteoporosis

(2015) F. Cosman et al.   OSTEOPOROSIS INTERNATIONAL

The Use of Alendronate Is Associated with a Decreased Incidence of Type 2 Diabetes Mellitus—A Population-Based Cohort Study in Taiwan

(2015) Ding-Cheng Chan et al.   PLoS One

Risk of fracture with thiazolidinediones: An updated meta-analysis of randomized clinical trials

(2014) Zhong-Ning Zhu et al.   BONE

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2014) Silvio E. Inzucchi et al.   DIABETES CARE

Fracture risk in diabetic elderly men: the MrOS study

(2014) Nicola Napoli et al.   DIABETOLOGIA

Safety Profile of Dapagliflozin for Type 2 Diabetes: Pooled Analysis of Clinical Studies for Overall Safety and Rare Events

(2014) Agata Ptaszynska et al.   DRUG SAFETY

Type 2 diabetes mellitus and fracture risk

(2014) Anastasia D. Dede et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Personalizing guidelines for diabetes management: twilight or dawn of the expert?

(2013) Stavroula A Paschou et al.   BMC Medicine

Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin

(2013) J. Bolinder et al.   DIABETES OBESITY & METABOLISM

Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus

(2013) Boaz Hirshberg et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Raloxifene modifies the insulin sensitivity and lipid profile of postmenopausal insulin resistant women

(2013) Fernando Grover-Páez et al.   GYNECOLOGICAL ENDOCRINOLOGY

Exendin-4, a Glucagon-Like Peptide-1 Receptor Agonist, Prevents Osteopenia by Promoting Bone Formation and Suppressing Bone Resorption in Aged Ovariectomized Rats

(2013) Xue Ma et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effects of antiresorptive therapies on glucose metabolism: Results from the FIT, HORIZON-PFT, and FREEDOM trials

(2013) Ann V Schwartz et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effects of Pioglitazone on Bone in Postmenopausal Women With Impaired Fasting Glucose or Impaired Glucose Tolerance: A Randomized, Double-Blind, Placebo-Controlled Study

(2013) Henry G. Bone et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Rosiglitazone Decreases Bone Mineral Density and Increases Bone Turnover in Postmenopausal Women With Type 2 Diabetes Mellitus

(2013) John P. Bilezikian et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control

(2013) Donald E. Kohan et al.   KIDNEY INTERNATIONAL

Estrogen or raloxifene during postmenopausal weight loss: Adiposity and cardiometabolic outcomes

(2013) R.E. Van Pelt et al.   Obesity

Canagliflozin: Effects in overweight and obese subjects without diabetes mellitus

(2013) Harold E. Bays et al.   Obesity

Use of glucagon-like peptide-1 receptor agonists and bone fractures: A meta-analysis of randomized clinical trials (胰高血糖素样肽-1受体激动剂的使用与骨折的关系：一项对随机临床试验的meta分析)

(2013) Guillaume Mabilleau et al.   Journal of Diabetes

Rosiglitazone Inhibits Bone Regeneration and Causes Significant Accumulation of Fat at Sites of New Bone Formation

(2012) Lichu Liu et al.   CALCIFIED TISSUE INTERNATIONAL

Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin

(2012) Ö. Ljunggren et al.   DIABETES OBESITY & METABOLISM

Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs

(2012) H. M. Colhoun et al.   DIABETOLOGIA

Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus

(2012) A H van Lierop et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studies

(2012) Lili Ma et al.   EUROPEAN JOURNAL OF EPIDEMIOLOGY

Effects of raloxifene on lipid and bone metabolism in postmenopausal women with type 2 diabetes

(2012) Hiroko Mori et al.   JOURNAL OF BONE AND MINERAL METABOLISM

Management of Hyperglycemia in Hospitalized Patients in Non-Critical Care Setting: An Endocrine Society Clinical Practice Guideline

(2012) Guillermo E. Umpierrez et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

European guidance for the diagnosis and management of osteoporosis in postmenopausal women

(2012) J. A. Kanis et al.   OSTEOPOROSIS INTERNATIONAL

Risk of Newly Diagnosed Type 2 Diabetes Is Reduced in Users of Alendronate

(2011) Peter Vestergaard   CALCIFIED TISSUE INTERNATIONAL

Dipeptidyl Peptidase-4 Inhibitors and Bone Fractures: A meta-analysis of randomized clinical trials

(2011) M. Monami et al.   DIABETES CARE

A randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-naïve type 2 d

(2011) J. L. C. Borges et al.   DIABETES OBESITY & METABOLISM

The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia

(2011) R. A. DeFronzo et al.   DIABETES OBESITY & METABOLISM

FRAX underestimates fracture risk in patients with diabetes

(2011) Lora M Giangregorio et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Rosiglitazone Decreases Bone Mass and Bone Marrow Fat

(2011) Torben Harsløf et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Prevalence of osteoporosis and vertebral fractures in postmenopausal women with type 2 diabetes mellitus and their relationship with duration of the disease and chronic complications

(2011) Maíra Viégas et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

The Peroxisome Proliferator-Activated Receptor-γ Agonist Rosiglitazone Increases Bone Resorption in Women with Type 2 Diabetes: A Randomized, Controlled Trial

(2010) Ugis Gruntmanis et al.   CALCIFIED TISSUE INTERNATIONAL

Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes

(2010) M. C. Bunck et al.   DIABETES OBESITY & METABOLISM

The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach

(2010) Paolo Pozzilli et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Effects of Raloxifene on Brachial Arterial Endothelial Function, Carotid Wall Thickness, and Arterial Stiffness in Osteoporotic Postmenopausal Women

(2010) Hiroyuki Sumino et al.   International Heart Journal

Thiazolidinedione Use and the Longitudinal Risk of Fractures in Patients with Type 2 Diabetes Mellitus

(2010) Zeina A. Habib et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Baseline atherosclerosis parameter could assess the risk of bone loss during pioglitazone treatment in type 2 diabetes mellitus

(2010) I. Kanazawa et al.   OSTEOPOROSIS INTERNATIONAL

Thiazolidinediones and Fractures in Men and Women

(2009) Colin R. Dormuth et al.   ARCHIVES OF INTERNAL MEDICINE

Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes

(2009) John Dormandy et al.   DRUG SAFETY

A Cohort Study of Thiazolidinediones and Fractures in Older Adults with Diabetes

(2009) Daniel H. Solomon et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effect of Rosiglitazone, Metformin, and Glyburide on Bone Biomarkers in Patients with Type 2 Diabetes

(2009) Bernard Zinman et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

(2009) Philip D Home et al.   LANCET

Effect of Raloxifene on Serum Lipids for Type 2 Diabetic Menopausal Women with or without Statin Treatment

(2009) Mihoko Matsumura et al.   MEDICAL PRINCIPLES AND PRACTICE

Use of Thiazolidinediones and Fracture Risk

(2008) Christian Meier et al.   ARCHIVES OF INTERNAL MEDICINE

Metformin enhances the differentiation and mineralization of osteoblastic MC3T3-E1 cells via AMP kinase activation as well as eNOS and BMP-2 expression

(2008) Ippei Kanazawa et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis

(2008) Y. K. Loke et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Effect of Exogenous Intermittent Recombinant Human PTH 1–34 Administration and Chronic Endogenous Parathyroid Hormone Excess on Glucose Homeostasis and Insulin Sensitivity

(2008) A. Anastasilakis et al.   HORMONE AND METABOLIC RESEARCH

Fracture Risk in Type 2 Diabetes: Update of a Population-Based Study

(2008) L Joseph Melton et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Association of Pioglitazone Treatment with Decreased Bone Mineral Density in Obese Premenopausal Patients with Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled Trial

(2008) Dorte Glintborg et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effects of raloxifene on insulin sensitivity, β-cell function, and hepatic insulin extraction in normal postmenopausal women

(2007) Manubai Nagamani et al.   FERTILITY AND STERILITY